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Objectives. This study was performed to determine the inci- 
dence of symptomatic, sustained atrial fibrillation in a group of 
patients with paroxysmal supraventricular tachycardia. The ef- 
fects of the mechanism of paroxysmal supraventricular tachycar- 
dia (atrioventricular [AV] node reentry vs. AV reentry through an 
accessory pathway) and heart rate during the tachycardia on the 
occurrence of atrial fibrillation were also assessed. 
Background. There is a substantial incidence of atrial fibrilla- 
tion in patients with paroxysmal supraventricular t chycardia, but 
the precise incidence and the factors that determine it are unknown. 
Methods. One hundred sixty-nine patients with paroxysmal 
supraventricular tachycardia were followed up by regular clinic 
visits and transtelephonic electrocardiographic monitoring dur- 
ing symptomatic episodes of arrhythmia. The Kaplan-Meier 
product-limit method was used to estimate the proportion of 
patients remaining free of atrial fibrillation during the observa- 
tion period. The Cox proportional hazards model was used to 
assess the effect of mechanism and heart rate during paroxysmal 
supraventricular t chycardia on the atrial fibrillation-free period. 
Results. Thirty-two (19%) of the 169 patients had an episode of 
atrial fibrillation during a mean follow-up period of 31 months. 
The cumulative percent of patients experiencing an episode of 
atrial fibrillation was 6% within 1 month, 9% within 4 months and 
12% within 1 year. The mechanism of paroxysmal supraventricu- 
lar tachycardia was not associated with the time to occurrence of 
atrial fibrillation; the hazard ratio corresponding toclassification 
in the AV node reentry group was 0.8 (p > 0.6). The heart rate 
during paroxysmal supraventricular tachycardia was not associ- 
ated with the time to occurrence of atrial fibrillation; the hazard 
ratio associated with an increase in heart rate of 50 beats/rain 
during the tachycardia was 1.15 (p > 0.5). 
Conclusions. This study suggests that atrial fibrillation will 
develop in -12% of patients with paroxysmal supraventricular 
tachycardia during a 1-year follow-up period. The occurrence of 
atrial fibrillation is not related to the mechanism or heart rate of 
the paroxysmal supraventricular tachycardia. 
(JAm CoU Cardiol 1995;25:984-8) 
Patients with paroxysmal supraventricular tachycardia occa- 
sionally experience atrial fibrillation. The most common mech- 
anisms of paroxysmal supraventricular tachycardia re atrio- 
ventricular (AV) node reentry and AV reentry through an 
accessory pathway. The occurrence of atrial fibrillation 
through the latter mechanism has been evaluated more exten- 
sively than that through other mechanisms, in part because of 
the potential for rapid conduction down the accessory pathway 
with resultant ventricular fibrillation and sudden cardiac death. 
There appears to be a greater incidence of atrial fibrillation in 
all patients with paroxysmal supraventricular tachycardia than 
in an age-matched normal population (1-3), but it is not known 
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whether the atrial fibrillation is related to the mechanism or 
the frequency of recurrence of the paroxysmal supraventricular 
tachycardia or to other factors. 
In this study, we evaluated the incidence of spontaneous 
episodes of atrial fibrillation in a large number of patients with 
various mechanisms of paroxysmal supraventricular tachycar- 
dia followed up over several years through transtelephonic 
electrocardiographic (ECG) monitoring. 
Methods  
Patient sample. Between February 1980 and November 
1993, 169 patients (85 men and 84 women) with paroxysmal 
supraventricular tachycardia were followed up by regular visits 
to our Clinical Research Unit Arrhythmia Clinic and by 
transtelephonic ECG monitoring to document the ECG during 
symptoms. Fifteen patients with a history of paroxysmal 
supraventricular tachycardia had also experienced one or more 
episodes of atrial fibrillation before entry into our follow-up 
study. The ECG criteria for paroxysmal supraventricular tachy- 
cardia were a ventricular ate >120 beats/rain, a QRS config- 
uration that was normal or reflected functional bundle branch 
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block, <20 ms variation in successive RR intervals, no evi- 
dence of AV dissociation, and episodic occurrence. The ECG 
criteria for atrial fibrillation were an irregularly irregular 
ventricular rhythm, a QRS configuration during arrhythmia 
that was normal or reflected functional bundle branch block, 
and no visible P waves. 
At the time of entry into the study, information was 
obtained regarding concomitant heart or lung disease and 
results of previous electrophysiologic studies. In addition to 
paroxysmal supraventricular tachycardia, 43 patients had heart 
disease, 25 had lung disease and 6 had both heart and lung 
disease. Eighty-seven patients underwent electrophysiologic 
study before or during the follow-up period with an intracar- 
diac (82 patients) or an esophageal lead (5 patients) recording 
and programmed lectrical stimulation todetermine the mech- 
anism of the tachycardia. The electrophysiologic studies were 
performed for clinical indications, not for research purposes. 
Patients who underwent electrophysiologic studies were 
classified according to the mechanism of tachycardia into four 
groups: 1) AV node reentry; 2) AV reentry through an 
accessory pathway; 3) ectopic atrial tachycardia; nd 4) un- 
known (if no tachycardia could be induced). 
Follow-up methods. Patients were given a transtelephonic 
ECG monitor (Cardiobeeper Memory Monitor, Survival Tech- 
nology) for their use in recording and transmitting a 30- to 45-s 
ECG during symptoms (4). The patients were contacted by a 
cardiologist or nurse within 24 h of receipt of the ECG to 
assess their symptoms. The rhythm strips were interpreted by a 
cardiologist and archived in laboratory log books. 
Medical therapy varied widely both before and during 
follow-up. It was generally our intent to withdraw all anti- 
arrhythmic drugs at some point during the follow-up period to 
document the occurrence of symptomatic events during a 
drug-free observation period; 150 of the 169 patients had such 
a drug-free period during follow-up (5). Drug therapy included 
digoxin, verapamil, diltiazem, atenolol, quinidine, disopyra- 
mide, propafenone or flecainide for part of the follow-up 
period. Some patients participated inresearch studies of these 
drugs, but most were treated for clinical indications (i.e., 
frequent episodes of paroxysmal supraventricular t chycardia). 
This protocol was approved by the Duke University Medi- 
cal Center Committee on Clinical Investigations. All patients 
gave written informed consent before participating. Some of 
the patients in this study have been the subjects of previous 
scientific reports (3,5,6). 
Data analysis. For the purposes of the analyses reported 
here, the observation period began on the day the patient was 
first seen in our clinic and given a transtelephonic ECG 
monitor; it continued until the patient was no longer being 
followed up by ECG monitor or until November 1, 1993, 
whichever occurred first. The length of the observation period 
varied, depending on the frequency of arrhythmic episodes and 
patient convenience, but we generally tried to monitor patients 
for at least several months. Patients who were still being 
followed up and had not had an outcome vent were censored 
as of November 1, 1993. The outcome variable of interest was 
the length of time from the beginning of the observation period 
to the first occurrence of atrial fibrillation. The Kaplan-Meier 
product-limit method was used to estimate and to illustrate 
graphically the proportion of patients remaining free of atrial 
fibrillation on each day of the observation period. 
To investigate the effect of the mechanism of paroxysmal 
supraventricular tachycardia on the length of time to the first 
occurrence of atrial fibrillation (the atrial fibrillation-free 
period), the patients were classified into one of three groups: 
1) patients with AV node reentrant tachycardia nduced uring 
an electrophysiologic study; 2) patients with AV reentrant 
tachycardia involving an accessory pathway induced uring an 
electrophysiologic study; 3) all other patients, including those 
who did not undergo an electrophysiologic study. Among the 
patients in the first two groups combined, the Cox proportional 
hazards model was used to assess the effect of mechanism on 
the atrial fibrillation-free period with and without adjustment 
for the potentially confounding effects of age and concomitant 
heart or lung disease. 
The proportional hazards model was also used to assess the 
effect of heart rate during paroxysmal supraventricular tachy- 
cardia on the recurrence time distribution of the atrial 
fibrillation-free period with and without adjustment for age 
and concomitant heart or lung disease. Heart rate during the 
first episode of paroxysmal supraventricular tachycardia in the 
observation period was used for this assessment. 
Resul ts  
Electrophysiologic study data. Of the 169 patients in the 
study, 87 had electrophysiologic studies. Forty-eight of the 87 
were classified as having AV reentry through an accessory 
pathway, 32 had AV node reentry, 2 had ectopic atrial 
tachycardia and 5 had no inducible arrhythmia. Of the 48 
patients whose mechanism was classified as AV reentry 
through an accessory pathway, 29 had an accessory pathway 
that functioned in both the anterograde and the retrograde 
direction, 18 had an accessory pathway that functioned in the 
retrograde direction only and 1 patient had a "pseudo-Mahaim 
fiber" (decremental anterograde-only atriofascicular ccessory 
pathway). 
One patient with AV node reentry induced uring electro- 
physiologic study also had an accessory AV pathway that 
functioned in the retrograde direction only and was not 
observed to participate in tachycardia. This patient was classi- 
fied as having AV node reentry as the mechanism of sponta- 
neous paroxysmal supraventricular t chycardia. The remaining 
48 patients with an AV accessory pathway proved by electro- 
physiologic study had inducible AV reentrant tachycardia. An 
attempt was made to induce atrial fibrillation during electro- 
physiologic study in most of these patients. In 38 of the 48 
patients, sustained (>30 s) atrial fibrillation was induced by 
single or double atrial extrastimuli or atrial burst pacing. Of 
the seven patients who had spontaneous atrial fibrillation, six 
had inducible, sustained atrial fibrillation; in the seventh 
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Figure 1. Graph showing time to occurrence of symptomatic 
atrial fibrillation in all 169 patients with paroxysmal supraven- 
tricular tachycardia. 
patient, who had an accessory, pathway with retrograde func- 
tion only, no attempt was made to induce atrial fibrillation. 
Of the 32 patients in whom atrial fibrillation developed, 
12 were taking no antiarrhythmic drugs at the time of its 
first occurrence during follow-up. The other 20 patients were 
taking a variety of antiarrhythmic drugs, including atenolol 
(n - 4), diltiazem (n - 3), verapamil (n = 3), propranolol (n = 
2), digoxin (n = 2), quinidine (n = 2), propafenone (n - 2), 
flecainide (n = 1) and disopyramide (n - 1) at the time of their 
first documented episode of paroxysmal trial fibrillation during 
follow-up. Because of the long folk)w-up time and frequent 
changes in medical therapy, we did not attempt o adjust the 
analysis on the basis of antiarrhythmic therapy. 
Length of time to occurrence of atrial fibrillation. 
Thirty-two (19%) of the 169 patients in this study had a 
symptomatic episode of atrial fibrillation that was recorded 
and documented by transtelephonic ECG. The mean observa- 
tion period was 956 days (31 months) (range 1 to 4,982 days 
[0 to 13 years]). The cumulative percent of patients experienc- 
ing an episode of atrial fibrillation was 6% within 1 month, 9% 
within 4 months and 12% within 1 year (Fig. 1). 
Of the 32 patients who experienced atrial fibrillation during 
the study period, 4 had one or more documented episodes of 
atrial fibrillation before entry, into our follow-up. 
For the 80 patients who had electrophysiologic studies and 
a tachycardia mechanism classified as either AV node reentry 
or AV reentry through an accessory pathway, the mechanism 
was not associated with the time to occurrence of atrial 
fibrillation (Fig. 2); the hazard ratio corresponding to mem- 
bership in the AV node reentry group was 0.8 (p > 0.6). 
Although the 32 patients with AV node reentrant tachycardia 
were older (mean age 44 vs. 31 years, p < 0.0001) and had a 
greater prevalence of heart and lung disease (44% vs. 25%, 
p < 0.10) than did the 48 patients whose mechanism was AV 
reentry through an accessory pathway, this hazard ratio re- 
mained insignificant (hazard ratio 0.6, p > 0.3) after adjust- 
ment for these two covariates (95% confidence interval [CI] for 
adjusted hazard ratio 0.14 to 2.2). 
The heart rate during paroxysmal supraventricular tachy- 
cardia was not significantly associated with the time to occur- 
rence of atrial fibrillation. The hazard ratio associated with an 
increase of 50 beats/rain in heart rate during paroxysmal 
supraventricular tachycardia was 1.15 (p > 0.05, 95% CI 0.71 
to 1.88) before and 1.24 (95% CI 0.72 to 2.14) after adjustment 
for age and presence of heart or lung disease. 
Discuss ion  
Incidence of atrial fibrillation. This study examined the 
occurrence of spontaneous atrial fibrillation in a large number 
of patients known to have paroxysmal supraventricular tachy- 
cardia. Previous studies (1,2) have noted the occurrence of 
spontaneous episodes of atrial fibrillation in 10% to 34% of 
Figure 2. Graph showing time to occurrence of symptomatic atrial 
fibrillation in the 80 patients with electrophysiologic studies who were 
classified as having atrioventricular node reentrant achycardia 
(dashed line, AV-NODAL) or atrioventricular reentry through an 
accessory pathway (solid line, Ace PATH). 
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patients with Wolff-Parkinson-White syndrome. Other studies 
from our patient population at Duke have noted an occurrence 
rate of atrial fibrillation of 22% in patients with paroxysmal 
supraventricular tachycardia of unknown mechanism (6) and 
18% in patients with proved AV node reentrant tachycardia 
after 1 year of follow-up (3). In the current study, the cumu- 
lative proportion of patients known to have paroxysmal su- 
praventricular tachycardia who experienced atrial fibrillation 
was 12% at 1 year. 
Effect of mechanism of paroxysmal supraventrieular tachy- 
cardia. Our study showed no significant difference in the 
incidence of atrial fibrillation between the patients with AV 
node reentrant tachycardia and those with AV reentry through 
an accessory pathway. This observation suggests that the 
occurrence of atrial fibrillation is not related to properties 
unique to patients with AV reentrant tachycardia through an 
accessory pathway, such as anterograde accessory pathway 
function, short anterograde effective refractory period of the 
accessory pathway or presence of multiple accessory pathways, 
as suggested by other investigators (7-9). 
Effect of heart rate during paroxysmal supraventrieular 
tachycardia. Heart rate during the first episode of paroxysmal 
supraventricular tachycardia was not associated with the time 
to occurrence of atrial fibrillation. Atrial vulnerability is in- 
creased at shorter cycle lengths as measured by repetitive atrial 
firing during atrial extrastimulus testing (10). However, studies 
of patients with AV reentrant tachycardia through an acces- 
sory pathway have shown no correlation between the cycle 
length of reciprocating tachycardia nduced during electro- 
physiologic study and the occurrence of atrial fibrillation 
(2,7,8). Our study confirms the lack of association between 
heart rate during spontaneous paroxysmal supraventricular 
tachycardia due to a variety of mechanisms and the occurrence 
of atrial fibrillation. 
Atrial fibrillation may develop in patients with paroxysmal 
supraventricular tachycardia s a result of factors not evalu- 
ated in this study. These include hemodynamic deterioration 
during the tachycardia, excessive atrial stretch or abnormalities 
of atrial conduction and refractoriness. Attempts by other 
investigators (2,8,9) to correlate variables uch as PA interval, 
atrial effective refractory period and dispersion of refractori- 
ness with the occurrence of atrial fibrillation have not pro- 
duced consistent results. 
Ablation of the accessory pathway in patients with Wolff- 
Parkinson-White syndrome leads to a significant reduction 
in the incidence of subsequent atrial fibrillation (9,11), 
suggesting that a functional reentrant circuit is usually 
necessary for the spontaneous induction of atrial fibrillation 
in these patients. Atrial fibrillation may occur as a result of 
sustained reciprocating tachycardia or as a result of prema- 
ture atrial stimulation during sinus rhythm due to retro- 
grade activation through the accessory pathway or the fast 
pathway of the AV node. If the cause of atrial fibrillation in 
these patients is sustained paroxysmal supraventricular 
tachycardia, the frequency of episodes of the tachycardia 
should be related to the occurrence of atrial fibrillation, but 
this association has not been rigorously tested. 
Risk of thromboembolic events. The occurrence of atrial 
fibrillation in patients with paroxysmal supraventricular 
tachycardia raises the issue of attendant thromboembolic 
risk. Previous tudies (12,13) have suggested that the risk of 
stroke is much less with paroxysmal trial fibrillation than 
with chronic atrial fibrillation and probably no higher than 
that in the general population. In contrast, the Stroke 
Prevention i  Atrial Fibrillation study (14) revealed that the 
incidence of thromboembolic events in patients with inter- 
mittent atrial fibrillation (5.6%/year) was equal to that of 
patients with chronic atrial fibrillation (5.9%/year). There 
are no data regarding the risk of thromboembolic events in 
patients who have both paroxysmal supraventricular t chy- 
cardia and paroxysmal trial fibrillation, but in the presence 
of other risk factors for thromboembolic events (e.g., con- 
gestive heart failure [12] or left atrial enlargement [15]), 
aspirin or warfarin therapy may be considered. The most 
effective antithrombotic therapy may be elimination of the 
reentrant circuit by treatment with antiarrhythmic drugs or 
radiofrequency ablation, thereby greatly diminishing the 
recurrence rate of atrial fibrillation. The effectiveness of
antiarrhythmic drug or ablation therapy on stroke preven- 
tion in these patients has not been tested. 
Limitations of the study. Our study was designed to assess 
the occurrence of episodes of symptomatic atrial fibrillation 
that were long enough for the patients to record an ECG; it did 
not include asymptomatic episodes or those too brief to record. 
Episodes of atrial fibrillation lasting only a few seconds are 
generally less bothersome to patients and rarely cause the 
hemodynamic compromise that is occasionally associated with 
sustained episodes. 
Because of the small number of patients who experienced 
atrial fibrillation in the groups with documented AV node 
reentrant tachycardia and AV reentrant tachycardia through 
an accessory pathway, our study may have failed to detect an 
important difference in the incidence of atrial fibrillation in 
the two groups. Although the use of antiarrhythmic drug 
therapy in some patients may have affected the occurrence 
rate of atrial fibrillation, it seems unlikely that it would have 
had a preferential effect on the occurrence of atrial fibril- 
lation in patients in one of the two groups. 
Conclusions. This study suggests that -12% of patients 
with paroxysmal supraventricular t chycardia will develop atrial 
fibrillation during a 1-year follow-up eriod. The occurrence of 
atrial fibrillation was not significantly related to mechanism or 
heart rate of paroxysmal supraventricular t chycardia, lthough 
the small number of events limits the conclusiveness of this 
observation. Further study is required to determine which other 
factors lead to development ofatrial fibrillation in patients with 
paroxysmal supraventricular t chycardia and whether the risk of 
thromboembolism warrants prophylaxis. 
We thank Mark Willis, BA for technical ssistance. 
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